aTyr Pharma, Inc.(US:ATYR) Prnewswireยท2025-10-10 05:12Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025, alleging that the company misled investors regarding the efficacy of its drug candidate, Efzofitimod [1][2]. Allegations - The lawsuit claims that aTyr Pharma provided misleading information about the Phase 3 study of Efzofitimod, which was designed to evaluate its safety and efficacy in patients with pulmonary sarcoidosis. The company's executives expressed confidence in the study's design while allegedly concealing the drug's inability to allow patients to taper off steroids completely [2]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48. Following this announcement, the stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in a single day [3]. Next Steps - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers to the court by December 8, 2025. Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4]. About Robbins LLP - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].